Skip to main content
NCBI home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1982 Feb;69(2):294–302. doi: 10.1172/JCI110452

Enhancement of Residual Arylsulfatase B Activity in Feline Mucopolysaccharidosis VI by Thiol-induced Subunit Association

Deborah T Vine 1,2,3,4, Margaret M McGovern 1,2,3,4, Edward H Schuchman 1,2,3,4, Mark E Haskins 1,2,3,4, Robert J Desnick 1,2,3,4
PMCID: PMC370978  PMID: 6799547

Abstract

The molecular pathology of the deficient arylsulfatase B activity in feline mucopolysaccharidosis (MPS) VI was investigated. Compared with the highly purified normal feline hepatic enzyme, the purified MPS VI residual activity had a 100-fold higher Michaelis constant (Km), an altered electrophoretic mobility, half the apparent native molecular weight, and markedly decreased thermo-, cryo-, and pH stabilities. Molecular weight and alkylation studies were consistent with the normal enzyme being a homodimer and the residual MPS VI enzyme a monomer. When incubated with various sulfhydryl reagents, the residual specific activity was enhanced several-fold, whereas the activity of the purified normal enzyme was un-affected or slightly inhibited. In the presence of dithiothreitol (DTT) and cysteamine, a lysosomotropic aminothiol, the residual activity had an electrophoretic mobility and native molecular weight similar to those of the normal feline enzyme. These findings suggested that the monomeric residual enzyme was dimerized in the presence of thiol-reducing agents. To determine if thiol-induced subunit association could therapeutically increase the residual activity and degrade the accumulated dermatan sulfate, in vitro and in vivo experiments were undertaken. When 2 mM DTT or cysteamine was incubated with heparinized whole blood from an MPS VI cat, the leukocyte residual arylsulfatase B activity increased 11- and 20-fold, respectively, and the accumulated dermatan sulfate was degraded in the presence of both thiol reagents. Intravenous administration of DTT (50 mg/kg) effected an immediate, but transient, increase in leukocyte residual activity; however, the substrate levels were not significantly decreased. In contrast, intravenous administration of cysteamine (15 mg/kg) increased leukocyte residual activity more than sixfold 30 min postinfusion; concomitantly, the leukocyte substrate was decreased to 35% of the initial level immediately after infusion and to about 45% of preinfusion values during the 120-min period studied. These results suggest that the defective residual activity in feline MPS VI can be therapeutically manipulated by thiol-induced subunit association. Furthermore, this animal analog provides a prototype for the investigation of human inborn errors of metabolism resulting from enzymatic defects that might be amenable to enzyme manipulation therapy.

Full text

PDF
294

Images in this article

298Image
on p.298

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bradford M. M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976 May 7;72:248–254. doi: 10.1016/0003-2697(76)90527-3. [DOI] [PubMed] [Google Scholar]
  2. Böhlen P., Stein S., Dairman W., Udenfriend S. Fluorometric assay of proteins in the nanogram range. Arch Biochem Biophys. 1973 Mar;155(1):213–220. doi: 10.1016/s0003-9861(73)80023-2. [DOI] [PubMed] [Google Scholar]
  3. Depape-Brigger D., Goldman H., Scriver C. R., Delvin E., Mamer O. The in vivo use of dithiothreitol in cystinosis. Pediatr Res. 1977 Feb;11(2):124–131. doi: 10.1203/00006450-197702000-00009. [DOI] [PubMed] [Google Scholar]
  4. Fluharty A. L., Stevens R. L., Sanders D. L., Kihara H. Arylsulfatase B deficiency in Maroteaux-Lamy syndrome cultured fibroblasts. Biochem Biophys Res Commun. 1974 Jul 24;59(2):455–461. doi: 10.1016/s0006-291x(74)80001-x. [DOI] [PubMed] [Google Scholar]
  5. Girardin E. P., DeWolfe M. S., Crocker J. F. Treatment of cystinosis with cysteamine. J Pediatr. 1979 May;94(5):838–840. doi: 10.1016/s0022-3476(79)80174-2. [DOI] [PubMed] [Google Scholar]
  6. Goldman H., Scriver C. R., Aaron K., Delvin E., Canlas Z. Adolescent cystinosis: comparisons with infantile and adult forms. Pediatrics. 1971 Jun;47(6):979–988. [PubMed] [Google Scholar]
  7. Goldman H., Scriver C. R., Aaron K., Pinsky L. Use of dithiothreitol to correct cystine storage in cultured cystinotic fibroblasts. Lancet. 1970 Apr 18;1(7651):811–812. doi: 10.1016/s0140-6736(70)92411-6. [DOI] [PubMed] [Google Scholar]
  8. Haskins M. E., Jezyk P. F., Patterson D. F. Mucopolysaccharide storage disease in three families of cats with arylsulfatase B deficiency: leukocyte studies and carrier identification. Pediatr Res. 1979 Nov;13(11):1203–1210. doi: 10.1203/00006450-197911000-00001. [DOI] [PubMed] [Google Scholar]
  9. Hedrick J. L., Smith A. J. Size and charge isomer separation and estimation of molecular weights of proteins by disc gel electrophoresis. Arch Biochem Biophys. 1968 Jul;126(1):155–164. doi: 10.1016/0003-9861(68)90569-9. [DOI] [PubMed] [Google Scholar]
  10. Jezyk P. F., Haskins M. E., Patterson D. F., Mellman W. J., Greenstein M. Mucopolysaccharidosis in a cat with arylsulfatase B deficiency: a model of Maroteaux-Lamy syndrome. Science. 1977 Nov 25;198(4319):834–836. doi: 10.1126/science.144321. [DOI] [PubMed] [Google Scholar]
  11. McGovern M. M., Vine D. T., Haskins M. E., Desnick R. J. An improved method for heterozygote identification in feline and human mucopolysaccharidosis VI, arylsulfatase-B deficiency. Enzyme. 1981;26(4):206–210. doi: 10.1159/000459176. [DOI] [PubMed] [Google Scholar]
  12. Percy A. K., Brady R. O. Metachromatic leukodystrophy: diagnosis with samples of venous blood. Science. 1968 Aug 9;161(3841):594–595. doi: 10.1126/science.161.3841.594. [DOI] [PubMed] [Google Scholar]
  13. REISFELD R. A., LEWIS U. J., WILLIAMS D. E. Disk electrophoresis of basic proteins and peptides on polyacrylamide gels. Nature. 1962 Jul 21;195:281–283. doi: 10.1038/195281a0. [DOI] [PubMed] [Google Scholar]
  14. Schuchman E. H., Desnick R. J. A new continuous, monodimensional electrophoretic system for the separation and quantitation of individual glycosaminoglycans. Anal Biochem. 1981 Nov 1;117(2):419–426. doi: 10.1016/0003-2697(81)90801-0. [DOI] [PubMed] [Google Scholar]
  15. Shapira E., DeGregorio R. R., Matalon R., Nadler H. L. Reduced arylsulfatase B activity of the mutant enzyme protein in Maroteaux-Lamy syndrome. Biochem Biophys Res Commun. 1975 Jan 20;62(2):448–455. doi: 10.1016/s0006-291x(75)80159-8. [DOI] [PubMed] [Google Scholar]
  16. Stumpf D. A., Austin J. H., Crocker A. C., LaFrance M. Mucopolysaccharidosis type VI (Maroteaux-Lamy syndrome). I. Sulfatase B deficiency in tissues. Am J Dis Child. 1973 Dec;126(6):747–755. doi: 10.1001/archpedi.1973.02110190597003. [DOI] [PubMed] [Google Scholar]
  17. Thoene J. G., Oshima R. G., Crawhall J. C., Olson D. L., Schneider J. A. Cystinosis. Intracellular cystine depletion by aminothiols in vitro and in vivo. J Clin Invest. 1976 Jul;58(1):180–189. doi: 10.1172/JCI108448. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Vine D. T., McGovern M. M., Haskins M. E., Desnick R. J. Feline mucopolysaccharidosis VI: purification and characterization of the resident arylsulfatase B activity. Am J Hum Genet. 1981 Nov;33(6):916–927. [PMC free article] [PubMed] [Google Scholar]
  19. Yudkoff M., Foreman J. W., Segal S. Effects of cysteamine therapy in nephropathic cystinosis. N Engl J Med. 1981 Jan 15;304(3):141–145. doi: 10.1056/NEJM198101153040303. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES